U.S. markets close in 5 hours 44 minutes
  • S&P 500

    -31.27 (-0.81%)
  • Dow 30

    -58.12 (-0.19%)
  • Nasdaq

    -210.00 (-1.57%)
  • Russell 2000

    -2.65 (-0.12%)
  • Crude Oil

    +1.07 (+1.79%)
  • Gold

    -25.80 (-1.49%)
  • Silver

    -0.77 (-2.86%)

    -0.0032 (-0.27%)
  • 10-Yr Bond

    +0.0610 (+4.31%)

    -0.0029 (-0.21%)

    +0.3570 (+0.33%)

    +1,389.80 (+2.82%)
  • CMC Crypto 200

    +26.54 (+2.69%)
  • FTSE 100

    +17.13 (+0.26%)
  • Nikkei 225

    +150.93 (+0.51%)

Meet Delta 9 Cannabis, A 2020 Benzinga Small Cap Conference Participant

  • Oops!
    Something went wrong.
    Please try again later.
Renato Capelj
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Benzinga held its inaugural Benzinga Global Small Cap Conference, a day of deal making, networking, and learning, on Dec. 8-9, 2020.

In recognition of those disruptive innovators creating positive and diverse change, Benzinga presents Delta 9 Cannabis Inc (OTC: VRNDF) (TSX: DN).

About: Founded in 2012, Delta 9 is a Canadian-based, vertically integrated cannabis company.

Through its in-house, state-of-the-art cultivation, processing, and dispensary capabilities, Delta 9 brings to wholesale and retail channels award-winning quality cannabis products.

In the simplest way possible: Delta 9 is a licensed provider of recreational cannabis, which it produces at an 85,000 square foot production facility in Winnipeg, Manitoba, Canada, and sells via its 8 retail store chain.

Core Offer Unpacked: Delta 9’s core focus revolves around leveraging the rapid innovation and growth in biotechnology to democratize access to recreational cannabis.

Through proprietary production techniques, Delta 9 is changing the way cannabis is grown and sold. Being one of Canada’s oldest licensed cannabis companies, Delta 9 uses years of know-how and experience to grow the depth and breadth of its product portfolio, diversifying revenue across wholesale, retail, and business-to-business segments.

Core offers include premium, blended flower and pre-roll products, as well as oil and other derivatives, all cultivated in Grow Pods -- modular, climate-controlled hydroponic systems that provide unique growing environments, stackable and mitigate contamination. Adding, Delta 9 also sells licensing and consulting, genetics solutions, as well as Grow Pods, thereby leveling the playing field and allowing other market participants access to consistently high yields and quality products in a turnkey platform.

In total, with its 297 Grow Pods, Delta 9’s current production capacity weighs in at a healthy 8,325 kg/year, helping keep its eight retail stores fully stocked and operational.

Prospects For Growth: In light of changing consumer preferences and regulations, Delta 9 is in the process of repositioning itself for the Cannabis 2.0 revolution.

This comes as the firm successfully grew its operations despite the pandemic.

“Our businesses have been declared essential through some of the shutdowns,” said Delta 9 CEO John Arbuthnot. “We’ve seen increased foot traffic and cart sizes, but overall we’ve been able to maintain operations. Obviously, health and safety protocols become top of mind -- ensuring physical distancing -- but overall, we have been able to maintain operations, and we have seen quite positive results.”

Going forward, the firm aims to expand its business-to-business division in the USA, retail operations in Western Canada, and derivative product offering.

“We’re always looking to add new markets,” the CEO added in a reference to growing beyond Delta 9’s immediate retail operations. “I think a large part of our strategy to continue to drive gains in our wholesale business will come from new supply agreements, ... putting us in Canada’s largest market -- six provincial supply agreements, representing well over 50% of the Canadian population now that Delta 9 products will be distributed in front of.”

To learn more about Delta 9, click here.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.